Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Vaginal Cancer: early-phase trial registry

7 of 12 indexed Vaginal Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 7 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Vaginal Cancer: 12 US clinical trials tracked, 7 recruiting.

Vaginal Cancer is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 3 of these trials.

Enrollment posture brief

Registry condition vaginal-cancer

OPEN 7 | RECR 58% | LATE 0 | EARLY 6 | RANK #1429 | SPON 3

Nearest open-share peer: Anterior Cruciate Ligament Reconstruction (58% recruiting · 12 trials)

Vaginal Cancer (this)58%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Vaginal Cancer

Vaginal Cancer lists 7 open slots (58% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Vaginal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Vaginal Cancer is recruiting above its size-band peers.

    7 of 12 indexed trials (58.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Vaginal Cancer research.

    Dana-Farber Cancer Institute accounts for 3 of 12 trials (25%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Vaginal Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 55 among the 12 trials that report a genuine target (sentinel values excluded). 10 of those (83.3%) plan for fewer than 100 participants.

  4. Vaginal Cancer research is mostly interventional.

    11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 25

Open and recent trials

12 total, page 1 of 1

RECRUITING 6,000 participants

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Northwestern University

NCT00005095

RECRUITING NA 192 participants

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

Northwestern University

NCT05743517

RECRUITING NA 70 participants

ASk Questions in GYnecologic Oncology (ASQ-GYO)

Ira Winer

NCT06339827

RECRUITING Phase 2 68 participants

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

University of Utah

NCT05979610

RECRUITING NA 54 participants

Image-Guided Gynecologic Brachytherapy

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02993900

RECRUITING Phase 2 32 participants

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Dana-Farber Cancer Institute

NCT06677190

RECRUITING Phase 2 20 participants

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Christian Hinrichs

NCT05686226

ACTIVE NOT RECRUITING Phase 1 55 participants

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

National Cancer Institute (NCI)

NCT04708470

COMPLETED Phase 2 93 participants

Image-Guided Gynecologic Brachytherapy

Dana-Farber Cancer Institute

NCT01399658

COMPLETED Phase 2 21 participants

Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers

Dana-Farber Cancer Institute

NCT00545792

COMPLETED NA 15 participants

Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer

University of Wisconsin, Madison

NCT02096783

COMPLETED NA 14 participants

Lymphoscintigraphy in Patients With Vaginal Cancer

M.D. Anderson Cancer Center

NCT00528034

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 5

Named interventions

Most-linked intervention names on Vaginal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

3'-Deoxy-3'-18f-Fluorothymidine Drug
1 trials
Image-guided brachytherapy Procedure
1 trials
Avastin Drug
1 trials
informational intervention Other
1 trials
Bintrafusp Alfa Drug
1 trials
counseling intervention Other
1 trials
screening questionnaire administration Other
1 trials
Ca-125 Other
1 trials

US sites by state

Facility locations filed on Vaginal Cancer trials. A trial with sites in several states counts in each.

Maryland 3 trials
Massachusetts 3 trials
Illinois 2 trials
Wisconsin 1 trials
Utah 1 trials
Texas 1 trials
New Jersey 1 trials
Michigan 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Vaginal Cancer page

12 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Vaginal Cancer condition card totals 12 registered trials; most-linked intervention 3'-Deoxy-3'-18f-Fluorothymidine; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.